Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment
BackgroundAbout 15 years ago, a diverse group of new recreational psychotropic substances began to emerge, which were marketed for example as “legal highs,” “research chemicals,” or “designer drugs.” These substances were later subsumed under the label “Novel Psychoactive Substances” (NPS). Importan...
Main Authors: | Michael Specka, Thomas Kuhlmann, Jürgen Sawazki, Udo Bonnet, Renate Steinert, Monika Cybulska-Rycicki, Helmut Eich, Benita Zeiske, Antje Niedersteberg, Luzia Schaaf, Norbert Scherbaum |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-07-01
|
Series: | Frontiers in Psychiatry |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fpsyt.2020.00569/full |
Similar Items
-
Corrigendum: Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment
by: Michael Specka, et al.
Published: (2021-04-01) -
Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment
by: Michael Specka, et al.
Published: (2022-06-01) -
The influence of tightening regulations on patients with new psychoactive substance‐related disorders in Japan
by: Yuko Tanibuchi, et al.
Published: (2018-12-01) -
The prevalence of novel psychoactive substances (NPS) use in non-clinical populations: a systematic review protocol
by: Salma M. Khaled, et al.
Published: (2016-11-01) -
Relationship of alexithymia to personality styles in people dependent on psychoactive substance
by: Roman Procházka, et al.
Published: (2014-12-01)